LFST · XBRL financial data
LifeStance Health Group financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (LFST's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 263 | 281* | 300 | 312 | 313 | 325* | 333 | 345 | 364 | 382* | 403 | 435 |
| Selling, general and administrative | 131 | 93* | 89 | 95 | 85 | 94* | 94 | 97 | 96 | 95* | 100 | 108 |
| Total operating expenses | 337 | 313* | 317 | 328 | 313 | 324* | 331 | 348 | 356 | 364* | 381 | 405 |
| Operating income (loss) | (74) | (32)* | (17) | (16) | 0 | 1* | 2 | (3) | 7 | 18* | 22 | 31 |
| Interest expense | 5 | 6* | 6 | 6 | 5 | 9* | 3 | 3 | 3 | 3* | 2 | 3 |
| Other income (expense) | — | — | — | — | — | — | — | (0) | — | — | — | (0) |
| Income tax expense (benefit) | (16) | 7* | 0 | 1 | 1 | (2)* | (2) | (2) | 3 | 4* | 6 | 4 |
| Net income (loss) | (62) | (45)* | (21) | (23) | (6) | (7)* | 1 | (4) | 1 | 12* | 14 | 24 |
| Weighted average shares, basic millions of shares | 0 | 0* | 376 | 379 | 380 | 380* | 383 | 387 | 387 | 387* | 387 | 384 |
| Weighted average shares, diluted millions of shares | 0 | 0* | 376 | 379 | 380 | 380* | 391 | 387 | 389 | 398* | 395 | 387 |
Balance sheet
CSVFiscal quarters (LFST's year ends in late December)
Cash flows
CSVFiscal quarters (LFST's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (62) | (45)* | (21) | (23) | (6) | (7)* | 1 | (4) | 1 | 12* | 14 | 24 |
| Stock-based compensation | 22* | 21* | 21 | 25* | 15* | 16* | 19 | 21* | 18* | 17* | 15 | 20* |
| Depreciation and amortization | 9 | 10* | 10 | 10 | 10 | 10* | 10 | 11 | 10 | 10* | 10 | 11 |
| Net cash from operating activities | (25)* | 17* | (22) | 44* | 23* | 62* | (3) | 64* | 27* | 58* | 33 | 100* |
| Purchases of property and equipment | 10* | 11* | 5 | 5* | 5* | 6* | 7 | 8* | 10* | 11* | 11 | 12* |
| Net cash from investing activities | (10)* | (11)* | (5) | (5)* | (5)* | (6)* | (7) | (8)* | (10)* | (11)* | (14) | (18)* |
| Share repurchases | — | — | — | — | — | — | 0 | 0* | — | — | 49 | 49* |
| Proceeds from long-term debt | 0* | 33* | — | — | 0* | 288* | — | — | — | year only | — | — |
| Repayments of long-term debt | 1* | 1* | 1 | 1* | 1* | 287* | 2 | 2* | 2* | 2* | 0 | 7* |
| Net cash from financing activities | (2)* | 31* | (2) | (1)* | (2)* | (4)* | (10) | (2)* | (2)* | (2)* | (73) | (51)* |
| Net change in cash | (37)* | 36* | (29) | 38* | 16* | 52* | (20) | 55* | 15* | 45* | (54) | 31* |
Compare with peers
SIC 8000 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8000 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| LifeStance Health Group | 226 | 435 | 100* | 382.1M | — | 10-QJun 30, 2026 |
| U S Physical Therapy | 25 | 214 | 34* | 14.9M | — | 10-QJun 30, 2026 |
| Pennant Group | 15 | 298 | 22* | 34.9M | — | 10-QJun 30, 2026 |
| Omada Health | 222 | 88 | 4* | 61.2M | — | 10-QJun 30, 2026 |
| GeneDx Holdings | 60 | 114 | (29)* | 29.8M | 4.6 quarters | 10-QJun 30, 2026 |
| Talkspace | 39 | 62 | 11* | 165.8M | — | 10-QJun 30, 2026 |
| Privia Health Group | 412 | not reported | 1.1* | 127.7M | — | 10-QJun 30, 2026 |
| Strata Critical Medical | 35 | 74 | 9.5* | 89.3M | — | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.